Plan by plan: who pays for tirzepatide in Colorado
Health First Colorado and CHP+
Colorado's Medicaid drug rule lists, among the drugs it excludes, "Agents when used for anorexia or weight loss" (10 CCR 2505-10 § 8.800). Legislative staff wrote in 2025 that members "with diabetes, moderate-to-severe OSA, or cardiovascular disease are already eligible for weight-loss medications that are FDA-approved for those conditions" (SB25-048 fiscal note, March 10, 2025). Its prior-authorization criteria sit on pages that refused our tools, so check with the program: Health First Colorado pharmacy benefits. A 2024 bill to cover obesity drugs in Medicaid, SB24-054, passed the Senate 24 to 10 and died in House Appropriations; analysts put its cost at $86.1 million in the first year, rising to $247.2 million (SB24-054; final fiscal note). CHP+ is written out of the 2027 law by name.
State employees, CU and other public employers
The State of Colorado's plan for about 40,000 employees began covering GLP-1s in September 2022. From July 1, 2025 it stopped covering new prescriptions for weight loss; employees already taking one kept coverage, and diabetes use was never part of the cut (Colorado Sun, May 20, 2025; Colorado Sun, January 23, 2025). We couldn't confirm the rules for the 2026-27 plan year, so check them with DPA: DPA, state employee medical benefits.
The University of Colorado pays its own claims. Its Exclusive plan for July 1, 2026 to June 30, 2027 lists "GLP-1 medications for weight loss: $100 copay per max 30-day fill" (CU Health Plan Exclusive, summary of benefits 2026-27). PERACare's 2027 booklet for public retirees states no weight-loss GLP-1 rule (PERACare 2027); ask your benefits office.
Job plans and the 2027 law
If your employer buys its plan from an insurer, the new rule starts at the plan's first issue or renewal on or after January 1, 2027. Ask HR two questions: is our plan insured or self-funded, and did we buy the anti-obesity drug option? Plans that pay their own claims follow federal law, not Colorado's, so the new rule doesn't reach them (our reading).
Pharmacy benefit managers move drugs too. CVS Caremark dropped Zepbound® for Wegovy® on its commercial lists on July 1, 2025 (CVS Health, June 27, 2025), then added Zepbound® back on October 1, 2026 "for plan sponsors who elect to provide coverage" (CVS Health, May 28, 2026).
Insurers' lists differ. Kaiser Permanente's 2027 Colorado marketplace list carries Wegovy® and no Zepbound®, and a listing isn't weight-loss coverage (Kaiser Permanente, 2027 drug list). UnitedHealthcare's Colorado individual lists carry only the diabetes drugs Mounjaro® and Ozempic® (UnitedHealthcare). Cigna's national Zepbound® policy asks for a BMI of 30, or 27 with a related condition (Cigna, Zepbound policy), and Cigna leaves Colorado's individual market on January 1, 2027 (Connect for Health Colorado, what's new).
Connect for Health Colorado and the Colorado Option
Plans you buy yourself, and small-employer plans, follow Colorado's benchmark plan, which excludes "Drugs for the treatment of weight control"; the benchmark for plan years from January 1, 2027 keeps that exclusion (CMS, essential health benefit benchmarks). Every insurer must also offer the Colorado Option, which follows the same benchmark, so it adds no weight-loss drug benefit (our reading). The 2027 sign-up window runs November 1, 2026 to January 15, 2027; enroll by December 15, 2026 to be covered from January 1 (Connect for Health Colorado).
Medicare and the GLP-1 Bridge
Part D members 18 or older who meet its BMI criteria pay $50 a month for Foundayo™, Wegovy® or the Zepbound® KwikPen® until December 31, 2027; it excludes type 2 diabetes, moderate to severe sleep apnea and fatty liver disease, and single-dose Zepbound® vials or pens (Medicare.gov; CMS). Compounded drugs aren't on its list. Free help: Colorado's Senior Health Insurance Assistance Program, (888) 696-7213 (CMS, SHIP directory).
TRICARE, the VA and tribal care
TRICARE "covers Wegovy, Saxenda, and Zepbound for weight management" for Prime and Select members with a network prescriber and prior authorization, but not for TRICARE For Life beneficiaries (TRICARE FAQ, updated August 6, 2026); for when that change took effect, check with TRICARE. For veterans, VA health care's criteria for Zepbound® are a BMI of 27 or more, a weight-related condition and a lifestyle program such as MOVE! (VA criteria for use, April 2026). The Indian Health Service formulary leaves weight-management criteria to each site (IHS formulary), so ask the Ute Mountain Ute Health Center in Towaoc or the Southern Ute Health Center in Ignacio.